Advanced Enzyme Technologies Q2 FY27 Earnings Presentation
Advanced Enzyme Technologies reported Q2 FY27 consolidated revenue of ₹2,145 million, up 16% YoY. EBITDA grew 20% to ₹721 million, and PAT increased 14% to ₹512 million. For H1 FY27, revenue was ₹4,062 million (up 10% YoY). Human Nutrition contributed 60% of revenue, while Industrial Bio-Processing saw 43% YoY growth.
The announcement provides detailed financial results and segment-wise performance, which are key factors for investors in evaluating the company's performance and future prospects.
The company reported positive year-on-year growth in revenue, EBITDA, and PAT for both the quarter and half-year periods, indicating strong financial performance.
Advanced Enzyme Technologies Limited has released its Earnings Presentation for the quarter and half-year ended September 30, 2026. The company reported consolidated revenue growth of 16% year-on-year to ₹2,145 million for Q2 FY27, up from ₹1,845 million in Q2 FY26. EBITDA saw a 20% increase to ₹721 million, and Profit After Tax (PAT) grew by 14% to ₹512 million.
On a sequential basis, revenue increased by 12% to ₹2,145 million in Q2 FY27 from ₹1,917 million in Q1 FY27. EBITDA surged by 36% to ₹721 million, and PAT rose by 33% to ₹512 million.
For the half-year ended September 30, 2027 (H1 FY27), revenue grew by 10% year-on-year to ₹4,062 million from ₹3,704 million in H1 FY26. EBITDA increased by 7% to ₹1,250 million, and PAT saw a 5% uptick to ₹897 million.
The Human Nutrition segment contributed 60% to the revenue, growing by 6% year-on-year to ₹1,285 million in Q2 FY27. Animal Nutrition contributed 12% of the revenue, showing a significant 37% growth year-on-year to ₹265 million in Q2 FY27. The Industrial Bio-Processing segment contributed 17% to revenue, with a robust 43% year-on-year growth to ₹365 million in Q2 FY27. Specialized Manufacturing contributed 11% to revenue, growing by 25% year-on-year to ₹231 million in Q2 FY27.
Geographically, India remains the largest market, contributing 52% of revenue in Q2 FY27, with a 25% year-on-year growth. Americas contributed 27% with 4% growth, while Europe contributed 13% with 6% growth. Asia (excluding India) contributed 5% with a 10% decline.
What to do with a filing like this
Advanced Enzyme Technologies Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Advanced Enzyme Technologies Limited. Read the original for the full detail.